Generate Biomedicines is a therapeutics company at the forefront of generative biology, combining machine learning, biological engineering, and medicine to create breakthrough medicines. Their innovative approach allows them to program protein-based modalities for the first time, revolutionizing drug development. With a focus on expanding what's scientifically possible in healthcare, they aim to maximize R&D productivity, build a pipeline of life-changing medicines, and create strategic partnerships. Their Generate Platform enables the generation of medicines on demand with unprecedented speed and success rates.

Gevorg Grigoryan

Generate Biomedicines

DVLP is building a new infrastructure for drug development by digitizing drug assets, financing, and development workflows to accelerate the process of turning molecules into medicines.

DVLP

Primordial AI utilizes evolutionary data and artificial intelligence to discover drug targets, focusing on achieving next-generation drug development.

Primordial AI

Pioneering generative biology to create breakthrough therapeutics.

Fidelity Management and Research Company

Morningside Venture Investments

Morningside Ventures

Flagship Pioneering

T. Rowe Price

Abu Dhabi Investment Authority

Alaska Permanent Fund

Altitude Life Science Ventures

ARCH Venture Partners

Generate:Biomedicines

ICYMI: At the 2023 The Galien Foundation Forum our CEO Michael Nally joined a panel of industry leaders titled “Conceiving, Creating and Building BioPharma Companies.”  
 
Mike and fellow panelists discussed the future of the biopharma industry – including the #AI revolution occurring at the intersection of biology and technology. As Mike shared: "I don't think a company can be born without a computational foundation going forward. I think it's going to be increasingly difficult to start companies without it." 
 
Learn more: https://lnkd.in/ewi6jSHY  

#UnapologeticallyScientific | #GenerativeBiology | #ProteinEngineering

In this article by Ryan Cross in Endpoints News, Alexandra Snyder, MD and Marco Davila discuss our new collaboration with Roswell Park Comprehensive Cancer Center. As Ryan states, we aim to “crack one of the toughest problems in cell therapy: getting CAR-T cells to target solid tumors.”   
 
In our collaboration, we will engineer and develop CAR-T drugs to treat solid tumors. These therapies are so-called "armored CARs" that include both a functionally optimized CAR protein and an additional factor targeting the harsh tumor microenvironment. 
 
Read more:  

#ProteinEngineering | #PatientFocusedDrugDevelopment

Today we announced a strategic collaboration with Roswell Park Comprehensive Cancer Center Park to discover and develop chimeric antigen receptor (CAR) T-cell therapies and armoring technologies for up to three oncology targets, including in ovarian cancer and other solid tumors. 
 
By combining the programmability and scalability of The Generate Platform with Roswell Park Comprehensive Cancer Center’s expertise in cell therapy design, clinical development, and manufacturing, we hope to bring best-in-class cell therapies to patients who are desperately in need of new treatment options. 
 
#GenerativeAI | #PatientFocusedDrugDevelopment 
 
Learn more:  https://lnkd.in/eRCy_mkB

On behalf of all of us at #TeamGenerate: Congratulations to fellow #FlagshipFounded company Tessera Therapeutics for receiving the Prix Galien 2023 Best Startup Award, which recognizes innovative emerging pharmaceutical enterprises making a profound impact on human health.

Today, Noubar Afeyan, Ph.D., our Co-founder and Chairman of the Board and Founder and Chief Executive Officer of Flagship Pioneering, presented the inaugural Chairman’s Award to John Ingraham, our Head of Machine Learning.  
 
The Chairman’s Award recognizes Generators for their commitment to answering daring "what if" questions by dreaming big, leaping boldly, and imagining alternative futures without constraint of reason.   
 
As a pioneer of #GenerativeBiology, John has applied his innovative thinking in #MachineLearning and #GenerativeAI to build tools that are making a profound impact on the field of #ProteinEngineering.  
 
Congratulations John for this exciting recognition!  
 
#FlagshipFounded | #UnapologeticallyScientific

On October 26, our CEO Michael Nally will speak as part of a The Galien Foundation Forum panel, “Conceiving, Creating and Building BioPharma Companies.” 
 
Chaired by John Maraganore, Founding CEO of Alnylam Pharmaceuticals, Mike and fellow panelists Sangeeta Bhatia, Professor of Electrical Engineering and Computer Science at MIT, Adam Koppel, Partner, Bain Capital Life Sciences, and Daphne Zohar, Founder & CEO of PureTech Health, will discuss the challenges and opportunities facing innovative new enterprises in the biotech industry.  
 
#GalienForum 
 
Learn more: https://bit.ly/3Fjkyxx

Jason Silvers, our Chief Financial Officer, will explore the evolving landscape of deal-making in a panel discussion at the Fierce Biotech Summit on October 17.  
 
Jason will offer his unique perspective on how biotech leaders can leverage strategic collaborations to drive innovation in an era of increasing market complexities.  

Learn more: https://bit.ly/48RMt5e

As a recipient of the 2023 Transform 10 Award, hear our Chief People Officer Beth Anton Grous talk about the future of work and how she’s capitalizing on these shifting sentiments to position our robust people-first culture for future growth.
 
#FiercelyUnited I #TeamGenerate

A recent Genetic Engineering & Biotechnology News article by MaryAnn L. highlights our work designing novel biologic drugs, including adeno-associated virus (AAV) therapies. 
 
Featuring Dr. Alexandra Snyder, MD, EVP of R&D, and Stephen Goldfless, PhD, Head of G:Labs Technology and Strategy, the article explains how we use The Generate Platform to overcome the challenges of pre-existing and adaptive immunity to therapeutics. 

#GenerativeAI | #ProteinEngineering

https://lnkd.in/eepSDw_G

On October 12, Adam Root, our VP of Protein Sciences, will explain how we are turning drug discovery into a technological pursuit in a webinar hosted by Drug Discovery World and Thermo Fisher Scientific. Learn more 👇 
 https://lnkd.in/eud_AxJS

Metric
Company Name	Generate Biomedicines	DVLP	Primordial AI
Symbol
MSH ID	COM:GENERATEBIOMEDICINES	COM:DVLPMEDICINES	COM:PRIMORDIALBIO
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals	Biotechnology
Country	US	US	US
Stage	Series C		Seed
Employee Count	283
Website	generatebiomedicines.com	dvlpmedicines.com	primordialbio.com
LinkedIn	generate-biomedicines	dvlpmedicines	primordial-ai
Founders

Metric
Market Cap	2.47B
Enterprise Value
Monthly Web Traffic	5.14K	133	1.24K
Web Traffic Growth	-0.02	-0.55	-0.54
Valuation
Raised Capital	273M		4M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:GENERATEBIOMEDICINES

Generate Biomedicines

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue